What do systematic reviews say?

Cefazolin plus amikacin vs vancomycin plus amikacin

It is very uncertain whether cefazolin plus amikacin changes all‐cause mortality maximum compared with vancomycin plus amikacin (very low certainty).

• Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 0.7 [0.29, 1.66]
  1 study · 109 participants
  Very low

Vancomycin plus gentamicin vs vancomycin plus aztreonam

It is very uncertain whether vancomycin plus gentamicin changes all‐cause mortality maximum compared with vancomycin plus aztreonam (very low certainty).

• Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 0.65 [0.2, 2.13]
  1 study · 81 participants
  Very low

Ticarcillin plus clavulanic acid vs flucloxacillin and gentamicin

It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with flucloxacillin and gentamicin (very low certainty).

• Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 3.82]
  1 study · 28 participants
  Very low

Cloxacillin plus amikacin vs cefotaxime plus gentamicin

It is very uncertain whether cloxacillin plus amikacin changes all‐cause mortality maximum compared with cefotaxime plus gentamicin (very low certainty).

• Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 0.38 [0.11, 1.27]
  1 study · 90 participants
  Very low

Meropenem vs usual care

It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).

• Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 1.42 [0.56, 3.62]
  1 study · 271 participants
  Very low

Ampicillin plus gentamicin vs penicillin plus gentamicin

It is very uncertain whether ampicillin plus gentamicin changes all‐cause mortality maximum compared with penicillin plus gentamicin (very low certainty).

• Antibiotic regimens for early‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 0.56 [0.3, 1.06]
  1 study · 283 participants
  Very low

Piperacillin vs ampicillin plus amikacin

It is very uncertain whether piperacillin changes all‐cause mortality maximum compared with ampicillin plus amikacin (very low certainty).

• Antibiotic regimens for early‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 0.62 [0.35, 1.1]
  1 study · 396 participants
  Very low

Ceftazidime vs 7 days injectable benzylpenicillin + injectable gentamicin

• Antibiotic regimens for early‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Very low

Piperacillin plus tazobactam vs amikacin

It is very uncertain whether piperacillin plus tazobactam changes all‐cause mortality maximum compared with amikacin (very low certainty).

• Antibiotic regimens for early‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 0.32 [0.01, 7.61]
  1 study · 59 participants
  Very low

Ticarcillin plus clavulanic acid vs piperacillin plus gentamicin

It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with piperacillin plus gentamicin (very low certainty).

• Antibiotic regimens for early‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 0.75 [0.19, 2.9]
  1 study · 72 participants
  Very low